The main play is obvious which is to make this as enticing as possible for a takeover.
Last year Otto Buttula retired from the board as late as the AGM , or such a mutually agreed , earlier time . Once either board renewal and an adequate handover , or a potential take over can be completed . The company remains in discussions with it advisors regarding attracting a new cornerstone shareholder , or full takeover.
Brian Leedman also retired from the board last year . He was a co- founder of Resapp ( RAP ) and did say they would never make any money but would still be acquired ( taken over ) which it was. The current Oncosil leadership team still consist of expertise from Sirtex which was taken over for $1.9 billion and Telix Pharmaceuticals TLX , around a $ 7 billion market cap. Brian Leedman has also mentioned that , You can only have a blockbuster product if a big pharma is selling it and mentioned Sirtex as a comparison and that is the ultimate outcome for Oncosil.
Ann: Comparative Analysis Indicates Benefits from OncoSil, page-26
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
95.0¢ |
Change
0.010(1.06%) |
Mkt cap ! $13.51M | |||
| Open | High | Low | Value | Volume |
| 95.0¢ | $1.02 | 94.0¢ | $110.7K | 114.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15628 | 95.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.00 | 1909 | 2 |
View Market Depth
| Last trade - 16.10pm 17/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |